Get the Daily Brief
Latest Biotech News
SPARK trial reports responses: sitravatinib plus tislelizumab in TNBC
Updated results from the SPARK phase II cohort indicate responses to the combination of sitravatinib, a tyrosine-kinase inhibitor, with tislelizumab, an anti–PD-1 antibody, in patients with...
New causal genes for diabetic nephropathy identified — TWAS and genomics
Researchers used transcriptome-wide association studies and genomic analyses to nominate novel causal genes linked to diabetic nephropathy. Two independent reports (Ma et al. and collaborators)...
PGS-hub benchmarks polygenic scores across ancestries — new standard
A Nature Communications study introduced PGS-hub, a benchmarking platform comparing single-ancestry and multi-ancestry polygenic scores across traits and populations. The authors (Chen, Wang, Zhao...
Antibiotic resistance is rising — four trends that could change the course
A field commentary outlined four major trends shaping antibiotic resistance: faster diagnostics, targeted stewardship, novel therapeutic platforms, and policy-driven incentives for development....
Erasca upsizes offering — $258.8M raised
Erasca (Nasdaq: ERAS) closed an upsized public offering, selling 25,875,000 shares at $10 to raise roughly $258.8 million. The proceeds will support the clinical-stage oncology company’s...
Qiagen in play: assessing strategic options
Bloomberg-reported interest has prompted Qiagen to evaluate strategic alternatives, including a potential sale, sending its shares higher. The life-science tools and diagnostics provider has held...
AnswersNow raises $40M to scale autism therapy
AnswersNow closed a $40 million Series B led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures, to expand access to its autism therapy platform. The funding...
Zarminali secures $110M Series A to rework pediatric care
Zarminali Pediatrics raised $110 million in a Series A led by Healthier Capital with participation from General Catalyst and K2 HealthVentures. The startup intends to use proceeds to scale...
SPARK trial: Sitravatinib plus tislelizumab shows activity in TNBC
The SPARK phase II multi-cohort single-arm trial reported activity for the combination of sitravatinib, a broad-spectrum tyrosine kinase modulator, with tislelizumab, an anti–PD‑1 antibody, in...
NK cell infusion shows safety signals in post‑transplant liver cancer
A phase I study of natural killer (NK) cell infusion in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation reported tolerability and preliminary antitumor signals....
Gut microbes shape cancer immunity — metabolites and population genomes
Two microbiome studies published recently advance links between gut communities and disease. Liu et al., in Molecular Cancer, reported that gut microbial metabolites modulate antitumor immunity,...
AI models sharpen proteomics and chromatin prediction
Two new computational tools apply machine learning to core molecular problems. ProteoBoostR debuted as an interactive supervised‑ML framework designed for clinical proteomics workflows, enabling...
Stroma and epigenetics drive lung cancer spread
Two mechanistic oncology studies identify non‑tumor drivers of metastasis. Rasbach et al. showed that a tumor‑intrinsic ITGB2 axis can be inhibited to suppress melanoma growth, revealing adhesion...
Moderna scales back vaccine investments amid US backlash
Moderna’s CEO told Bloomberg the company is curbing investments in some vaccine trials in response to political and public backlash in the United States. The shift reflects pressure on mRNA...
Biotech cash sprint: Erasca raises $258.8M – Corxel banks $287M
Biotech capital markets delivered two large financing events this week. Erasca closed an upsized public offering of 25.875 million shares at $10.00 per share, generating roughly $258.8 million in...
Appeals court remands Guardant-TwinStrand feud: patent validity sent back to PTAB
A U.S. appeals court has remanded parts of the patent dispute between Guardant Health and TwinStrand Biosciences back to the Patent Trial and Appeal Board (PTAB) for further consideration. The...
Encodia shutters: protein sequencing start‑up ceases operations
Encodia, a San Diego firm developing ProteoCode DNA‑tagged peptide protein sequencing, has ceased operations and entered an assignment for the benefit of creditors. The company, launched by...
Novartis expands RNAi push — CEO outlines de‑risking strategy
Novartis signaled an expanded commitment to RNA interference (RNAi) as a therapeutic modality, with CEO Vas Narasimhan describing a deliberate, de‑risking approach to build on recent modality...
Sanofi moves forward with amlitelimab filings... despite mixed Phase III reads
Sanofi announced plans to pursue global regulatory submissions for amlitelimab in atopic dermatitis, citing the totality of data despite mixed Phase III results. The OX40‑ligand inhibitor met...
Macrophage‑targeting CAR T reprograms tumor microenvironment — survival improves in models
Researchers at the Icahn School of Medicine reported an experimental CAR T approach that targets tumor‑associated macrophages (TAMs) and secretes IL‑12, reprogramming the tumor microenvironment...